Market Overview

Following Extended Consolidation Period, Biotech ETF's Next Breakout Could Be Big

Share:
Following Extended Consolidation Period, Biotech ETF's Next Breakout Could Be Big
Related IBB
Breaking Up The Boys Club: Mish Schneider Talks Trading Floor Culture, The Market's 'Modern Family'
Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold
Vaccine Small-Cap Just Took a Big Step Forward (GuruFocus)

After some huge swings in the past three years, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has been relatively quiet for the past few months, trading mostly sideways within a very narrow range. The extended consolidation period may mean the IBB’s next breakout will be a big one. Traders simply have to figure out whether that move will be up or down.

IBB peaked at $399.60 back in the summer of 2015. By February 2016, IBB was all the way back down making 52-week lows below $240. The ETF's multi-year low of $239.34 from February 2016 has held as a support level ever since. IBB found support in the $240–$248 range five times throughout 2016 as it bounced between $240 and $300 throughout the year.

Related Link: The Latest On Drug Pricing, Healthcare Bill As Senate Takes Up Issue In Earnest

After a brief dip to $270 early in the year, IBB has spent the past five months trading in a much narrower range near the top of its previous range. Since mid-February, IBB has found support several times in the $285 range, but it has repeatedly failed to break out above $300.

The two major support (green) and resistance (red) lines are included in the chart below.

Volume has been relatively low throughout this five-month stretch, and the trading range has been very narrow, suggesting the stock is consolidating ahead of its next major move. Traders will be looking for a breakout on high volume either above $300 or below $285.

If IBB breaks above $300, it could be headed as high as $343, where it ran into resistance a few times in late 2015. If it breaks down below $285, it could be headed back to the low end of its longer-term range, meaning a dip to the $240—$248 level could be in the cards.

Joel Elconin contributed to this article.

Posted-In: BiotechBiotech Sector ETFs Technicals Top Stories Trading Ideas ETFs General Best of Benzinga

 

Related Articles (IBB)

View Comments and Join the Discussion!